Alumis (ALMS) Intangibles (2025 - 2026)

Alumis (ALMS) posted quarterly Intangibles of $51.0 million for Q4 2025, little changed quarter-over-quarter from $51.0 million in Q3 2025.

Analysis

Alumis (ALMS) Intangibles (2025 - 2026) Analysis & Trends

Alumis (ALMS) has reported Intangibles for 1 consecutive years, with $51.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Intangibles changed N/A year-over-year to $51.0 million; the TTM figure through Dec 2025 stood at $51.0 million (changed N/A YoY), while the FY2025 annual figure was $51.0 million, changed N/A from the prior year.
Intangibles was little changed at $51.0 million in Q4 2025 per ALMS's latest filing, from $51.0 million in the prior quarter.
Across five years, Intangibles topped out at $51.0 million in Q2 2025 and bottomed at $51.0 million in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	63.28 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	60.96 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	93.49 Mn
10	Alumis	1.42 Bn	919.00 Mn	-	9.14 Mn

Historic Data

Download Data